MET and hepatocellular carcinoma: To further model c-MET/sgp53 mouse liver tumors to human HCCs, we analyzed a subset of human HCC samples harboring concomitant c-MET activation and TP53 deletion using the TCGA-LIHC dataset, which occurred in 23/360 HCC specimens (Fig. S8A).